Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.50 |
| ▸ | MMP13 | P45452 | 10/20 | 0.50 |
| ▸ | MMP1 | P03956 | 6/20 | 0.50 |
| ▸ | MMP9 | P14780 | 6/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 4/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16460244 | 0.82 | ADAM17 (0.56) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL16460245 | 0.82 | ADAM17 (0.56) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL16460279 | 0.80 | ADAM17 (0.58) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL16460282 | 0.80 | ADAM17 (0.58) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL14245046 | 0.76 | ADAM17 (0.60) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL997543 | 0.76 | ADAM17 (0.53) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL14245113 | 0.72 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL996097 | 0.72 | ADAM17 (0.75) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6508472 | 0.69 | ADAM17 (0.76) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL995893 | 0.69 | ADAM17 (0.61) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980897-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-03-17 | — | — | US | disclosed |
| US-20140107129-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107129-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, NISCH | ADAM17 3157/4885MMP13 2854/4885MMP1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.